312 related articles for article (PubMed ID: 7671552)
1. C-peptide response to glucagon in type 2 diabetes mellitus: a comparison with oral glucose tolerance test.
Iwasaki Y; Kondo K; Hasegawa H; Oiso Y
Diabetes Res; 1994; 25(3):129-37. PubMed ID: 7671552
[TBL] [Abstract][Full Text] [Related]
2. The role of diminished beta cell reserve and insulin resistance in secondary sulfonylurea failure of type 2 diabetes mellitus.
Rattarasarn C; Thamprasit A; Leelawattana R; Soonthornpun S; Setasuban W
J Med Assoc Thai; 2001 Dec; 84(12):1754-62. PubMed ID: 11999824
[TBL] [Abstract][Full Text] [Related]
3. Secretory protein 7B2 response to oral glucose loading and intravenous glucagon injection in patients with diabetes mellitus.
Hisatomi A; Natori S; Iguchi H; Ohashi M; Umeda F; Nawata H
Fukuoka Igaku Zasshi; 1996 Dec; 87(12):266-73. PubMed ID: 9011109
[TBL] [Abstract][Full Text] [Related]
4. Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes.
Hare KJ; Vilsbøll T; Holst JJ; Knop FK
Am J Physiol Endocrinol Metab; 2010 Apr; 298(4):E832-7. PubMed ID: 20103744
[TBL] [Abstract][Full Text] [Related]
5. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
[TBL] [Abstract][Full Text] [Related]
6. Influence of exogenous insulin on C-peptide levels in subjects with type 2 diabetes.
Albareda M; Rigla M; Rodríguez-Espinosa J; Caballero A; Chico A; Cabezas R; Carreras G; Pérez A
Diabetes Res Clin Pract; 2005 Jun; 68(3):202-6. PubMed ID: 15936461
[TBL] [Abstract][Full Text] [Related]
7. Insulin and C-peptide responses to 75 g oral glucose load in the healthy man.
Bonora E; Zavaroni I; Alpi O; Pezzarossa A; Bruschi F; Guerra L; Dall'Aglio E; Coscelli C; Butturini U
Diabete Metab; 1986 Jun; 12(3):143-8. PubMed ID: 3525269
[TBL] [Abstract][Full Text] [Related]
8. Non-insulin-dependent diabetes: 10-year outcome in relation to initial response to diet and subsequent sulfonylurea therapy.
Sönksen PH; Lowy C; Perkins JR; Lim HS
Diabetes Care; 1984; 7 Suppl 1():59-66. PubMed ID: 6376030
[TBL] [Abstract][Full Text] [Related]
9. The impact of treatment on insulin release and relative peripheral resistance during the oral glucose tolerance test. A study of noninsulin-dependent diabetes mellitus and glucose intolerance.
Cederholm J; Wibell L
Diabete Metab; 1986 Feb; 12(1):10-5. PubMed ID: 3516748
[TBL] [Abstract][Full Text] [Related]
10. Intrapulmonary administration of natural honey solution, hyperosmolar dextrose or hypoosmolar distill water to normal individuals and to patients with type-2 diabetes mellitus or hypertension: their effects on blood glucose level, plasma insulin and C-peptide, blood pressure and peaked expiratory flow rate.
Al-Waili N
Eur J Med Res; 2003 Jul; 8(7):295-303. PubMed ID: 12911866
[TBL] [Abstract][Full Text] [Related]
11. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
[TBL] [Abstract][Full Text] [Related]
12. [C-peptide levels in secondary sulfonylurea resistant diabetics].
Balázsi I; Takács J; Hargitai G
Orv Hetil; 1993 Dec; 134(52):2859-62. PubMed ID: 8272351
[TBL] [Abstract][Full Text] [Related]
13. Impaired circulating glucagon-like peptide-1 response to oral glucose in women with previous gestational diabetes.
Forbes S; Moonan M; Robinson S; Anyaoku V; Patterson M; Murphy KG; Ghatei MA; Bloom SR; Johnston DG
Clin Endocrinol (Oxf); 2005 Jan; 62(1):51-5. PubMed ID: 15638870
[TBL] [Abstract][Full Text] [Related]
14. Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals.
DeFronzo RA; Simonson DC
Diabetes Care; 1984; 7 Suppl 1():72-80. PubMed ID: 6428844
[TBL] [Abstract][Full Text] [Related]
15. Plasma glucose response after intravenous injection of tolbutamide in insulin-treated type I and type II diabetic patients.
Mokuda O; Murakami I; Ikeda T; Tominaga M; Mashiba H
Exp Clin Endocrinol; 1988 Aug; 91(3):265-70. PubMed ID: 3075183
[TBL] [Abstract][Full Text] [Related]
16. Effect of dihydroxyacetone and pyruvate on plasma glucose concentration and turnover in noninsulin-dependent diabetes mellitus.
Stanko RT; Mitrakou A; Greenawalt K; Gerich J
Clin Physiol Biochem; 1990; 8(6):283-8. PubMed ID: 2132162
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of beta cell function in non-insulin-dependent diabetes mellitus (NIDDM) and its correlations with clinico-metabolic parameters].
Santoro E; Gianni R; Maggi L; Tomassini CR; Bisacchi U
G Clin Med; 1989 Feb; 70(2):95-9. PubMed ID: 2666224
[TBL] [Abstract][Full Text] [Related]
18. Correction of fasting hyperglycaemia with insulin or sulphonylurea lowers fasting ketone levels, but does not alter resting or post-glucose energy expenditure in non insulin dependent diabetes. Differences between the OGTT and the glucose clamp.
Boyd K; Boreham C; Andrews WJ; Hadden DR
Diabetes Res; 1991 Nov; 18(3):101-8. PubMed ID: 1841819
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic B-cell function in non-insulin-dependent diabetes mellitus during successive periods of sulfonylurea and insulin treatment: serum C-peptide response to glucagon and urine C-peptide excretion.
Hsieh SD; Iwamoto Y; Matsuda A; Kuzuya T
Endocrinol Jpn; 1987 Aug; 34(4):561-7. PubMed ID: 3315640
[TBL] [Abstract][Full Text] [Related]
20. Increment of serum C-peptide measured by glucagon test closely correlates with human relative beta-cell area.
Fujita Y; Kozawa J; Iwahashi H; Yoneda S; Uno S; Yoshikawa A; Okita K; Eguchi H; Nagano H; Imagawa A; Shimomura I
Endocr J; 2015; 62(4):329-37. PubMed ID: 25740613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
